Emergent BioSolutions to Acquire Cangene Corporation
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding...
Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia
Emergent BioSolutions Inc. (NYSE:EBS) today announced positive interim results from a Phase 2 study evaluating the combination of otlertuzumab (TRU-016) and bendamustine versus bendamustine alone in...
Emergent BioSolutions to Webcast Presentation at the 32nd Annual J.P. Morgan Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January...
Emergent BioSolutions Appoints A.B. Cruz III as Executive Vice President and General Counsel
Emergent BioSolutions Inc. (NYSE:EBS) announced today the appointment of A.B. Cruz III as executive vice president and general counsel responsible for managing all legal matters involving securities,...
Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will lead a discussion, which may involve recent business developments and financial...
Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual Meeting
Emergent BioSolutions Inc. (NYSE: EBS) announced today that two abstracts on its humanized anti-CD37 mono-specific protein therapeutic, otlertuzumab (TRU-016), being evaluated in patients with...
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the third quarter and nine months ended September 30,...
Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) therapeutic, ES414, at the 5th Annual Protein...
Emergent BioSolutions Wins 2013 North American Maintenance Excellence Award
Emergent BioSolutions (NYSE:EBS) today announced that its facility in Lansing, Michigan has been recognized with the 2013 North American Maintenance Excellence (NAME) Award by the Foundation for...
Emergent BioSolutions to Webcast Presentation at Credit Suisse 2013 Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2013 Healthcare Conference in Scottsdale, Arizona on Tuesday, November...
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in Combination with Rituximab in People with CLL
Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination...
Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call on November 7, 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the third quarter 2013 on Thursday, November 7, 2013, after market...